Innovative antibody for

personalized medicine

TheraMAB LLC presents new clinical data on theralizumab (TAB08) at Nature Biotechnology

Moscow, Russia, December 2014

TheraMAB presents new data on theralizumab published in Nature Biotechnology special issue Biopharma Dealmakers:
- TheraMAB is progressing clinical development of its novel regulatory T-cell activator for use in rheumatoid arthritis and other autoimmune diseases based on encouraginginterimresults of its continuing phase 1b clinical trial.
- The mechanism of action and good preclinical data suggest that TAB08 may also be effective for treating other autoimmune diseases such as SLE and psoriasis.

Following presentation at Bio 2014 TheraMAB CEO Dr. Tyrsin was encouraged to publish its interesting data at Nature Biotechnology in a special issueBiopharma Dealmakers. In this advertising article TheraMAB overviews the history of the molecule, the novel methods used to further characterize mechanism of action of TAB08 in preclinical models. Special attention is brought to recent clinical data in healthy volunteers and patients with rheumatoid arthritis. It has been demonstrated that theralizumab can be administered safely to healthy volunteers and RA patients, and preliminary phase 1b findings show promising clinical effect data.

“The presentation of our phase 1a/b results at recent meetings has drawn significant interest from both scientists and clinicians,” - said Tyrsin. “The results obtained are very encouraging. TAB08 has the potential to meet the substantial medical need of patients suffering from RA and other autoimmune diseases. “Now we are glad that interest in our project resulted in very prestigious journal Nature Biotechnology. And it will help us complete the next stages of clinical development of our first-in-class humanized monoclonal antibody of the IgG4 subclass”, - Tyrsin added.

More information can be found athttp://viewer.zmags.com/publication/a12191bd#/a12191bd/14.

Download PDF.

About TAB08

The medicinal product which is being developed by the company TheraMAB LLC represents the “first-in-class”, humanized mAb of IgG4 class, which mode of action is based on binding to costimulating receptor CD28, specific for human Т-lymphocytes. CD28 receptor is expressed on majority of human CD4+ Т-cells, where it effectively costimulates activation and proliferation of Т-cells. The uniqueness of mode of action of ТАВ08s compared to other mAbs lies in the ability of the antibody to affect key aspects of pathogenesis via normalization of functional balance of various immune cell. Opposite to TAB08, majority of other antibodies (TNFa, IL-1, IL-6, etc.) address only the consequences of autoimmune diseases by neutralizing secreted pro-inflammatory factors produced.